Since head-to-head trials comparing the different treatment regimens have not yet been published, it remains a vital issue for cutaneous oncologists to determine the most suitable first-line therapeutic option and the optimal treatment sequencing of BRAF/MEKi therapy and CPI for BRAF-mutant melanoma patients. Here, BRAF is linked to melanoma.